118 related articles for article (PubMed ID: 16775878)
1. Advances in the treatment of hematologic malignancies. Part 1 of a 3-part series: Aggressive lymphomas.
Fisher RI; Coiffier B; Vose JM
Clin Adv Hematol Oncol; 2006 Apr; 4(4):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. PubMed ID: 16775878
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
3. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
4. [Treatment options in non-Hodgkin lymphomas].
Tilly H
Rev Prat; 2010 Jan; 60(1):69-74. PubMed ID: 20222315
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of B-cell lymphomas.
Weiner G
Clin Adv Hematol Oncol; 2007 Jul; 5(7):510-2. PubMed ID: 17679923
[No Abstract] [Full Text] [Related]
8. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
9. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S
Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574
[TBL] [Abstract][Full Text] [Related]
10. New concepts in treatment approaches and prognostic factors in aggressive NHL.
Shipp M
Clin Adv Hematol Oncol; 2006 Feb; 4(2):107-9. PubMed ID: 16728917
[No Abstract] [Full Text] [Related]
11. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
12. New treatment strategies in lymphomas: aggressive lymphomas.
Coiffier B
Ann Hematol; 2004; 83 Suppl 1():S73-4. PubMed ID: 15124681
[TBL] [Abstract][Full Text] [Related]
13. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
[TBL] [Abstract][Full Text] [Related]
14. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
15. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
Robledo C; García JL; Caballero D; Conde E; Arranz R; Flores T; Grande C; Rodríguez J; García E; Sáez AI; González M; Gutiérrez NC; Piris MA; Hernández JM;
Cancer; 2009 Aug; 115(16):3728-37. PubMed ID: 19517471
[TBL] [Abstract][Full Text] [Related]
16. Diffuse large B-cell lymphoma.
Ng AK
Semin Radiat Oncol; 2007 Jul; 17(3):169-75. PubMed ID: 17591563
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.
Held G; Schubert J; Reiser M; Pfreundschuh M;
Semin Hematol; 2006 Oct; 43(4):221-9. PubMed ID: 17027656
[TBL] [Abstract][Full Text] [Related]
18. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
19. Treatment strategies in follicular lymphomas: current status and future perspectives.
Hiddemann W; Buske C; Dreyling M; Weigert O; Lenz G; Forstpointner R; Nickenig C; Unterhalt M
J Clin Oncol; 2005 Sep; 23(26):6394-9. PubMed ID: 16155025
[TBL] [Abstract][Full Text] [Related]
20. Primary mediastinal large B-cell lymphoma.
Martelli M; Ferreri AJ; Johnson P
Crit Rev Oncol Hematol; 2008 Dec; 68(3):256-63. PubMed ID: 18774728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]